title: SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions.
abstract: It is now clear that NSPs (neutrophil serine proteases), including elastase, Pr3 (proteinase 3) and CatG (cathepsin G) are major pathogenic determinants in chronic inflammatory disorders of the lungs. Two unglycosylated natural protease inhibitors, SLPI (secretory leucocyte protease inhibitor) and elafin, and its precursor trappin-2 that are found in the lungs, have therapeutic potential for reducing the protease-induced inflammatory response. This review examines the multifaceted roles of SLPI and elafin/trappin-2 in the context of their possible use as inhaled drugs for treating chronic lung diseases such as CF (cystic fibrosis) and COPD (chronic obstructive pulmonary disease).
authors.affiliation: INSERM U618, Protéases et Vectorisation Pulmonaires, Faculté de Médecine, 10 Bd Tonnellé, 37032 Tours Cedex, France.
authors.forename: Marie-Louise
authors.initials: ML
authors.lastname: Zani
authors.forename: Annabelle
authors.initials: A
authors.lastname: Tanga
authors.forename: Ahlame
authors.initials: A
authors.lastname: Saidi
authors.forename: Hélène
authors.initials: H
authors.lastname: Serrano
authors.forename: Sandrine
authors.initials: S
authors.lastname: Dallet-Choisy
authors.forename: Kévin
authors.initials: K
authors.lastname: Baranger
authors.forename: Thierry
authors.initials: T
authors.lastname: Moreau
mesh_terms: D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use; D000935:Antifungal Agents / Q000378:metabolism / Q000627:therapeutic use; D053492:Elafin / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology*; D008171:Lung Diseases / Q000188:drug therapy / Q000201:enzymology*; D053491:Proteinase Inhibitory Proteins, Secretory / Q000378:metabolism / Q000627:therapeutic use; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000378:metabolism* / Q000627:therapeutic use; D057057:Serine Proteases / Q000378:metabolism*; D015842:Serine Proteinase Inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D011503:Transglutaminases / Q000378:metabolism
chemical_list: D000336:Aerosols; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D053492:Elafin; C506806:PI3 protein, human; D053491:Proteinase Inhibitory Proteins, Secretory; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D015842:Serine Proteinase Inhibitors; D011503:Transglutaminases; D057057:Serine Proteases